Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer.
about
Identification and characterization of a novel androgen receptor coregulator ARA267-alpha in prostate cancer cellsBiologic and clinical significance of androgen receptor variants in castration resistant prostate cancerNotch signaling in prostate cancer: a moving targetAn androgen receptor NH2-terminal conserved motif interacts with the COOH terminus of the Hsp70-interacting protein (CHIP)Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptorAndrogen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo.Mutation of the androgen receptor causes oncogenic transformation of the prostateMouse models of prostate cancer: picking the best model for the question.The N-terminal domain of the androgen receptor drives its nuclear localization in castration-resistant prostate cancer cellsMutations in the helix 3 region of the androgen receptor abrogate ARA70 promotion of 17beta-estradiol-induced androgen receptor transactivation.Androgen receptor signaling and mutations in prostate cancerThe emergence of resistance to targeted cancer therapeutics.Early growth inhibition is followed by increased metastatic disease with vitamin D (calcitriol) treatment in the TRAMP model of prostate cancerAndrogen receptor gene polymorphisms and alterations in prostate cancer: of humanized mice and men.Expression and function of nuclear receptor co-activator 4: evidence of a potential role independent of co-activator activity.Androgen receptor variants and prostate cancer in humanized AR mice.Early and delayed castrations confer a similar survival advantage in TRAMP miceGene signatures distinguish stage-specific prostate cancer stem cells isolated from transgenic adenocarcinoma of the mouse prostate lesions and predict the malignancy of human tumors.Targeted therapy of cancer: new roles for pathologists--prostate cancer.Diverse roles of androgen receptor (AR) domains in AR-mediated signaling.Profiling human androgen receptor mutations reveals treatment effects in a mouse model of prostate cancerTreatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.The role of androgen receptor mutations in prostate cancer progression.Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy.Progress in the mechanism and drug development of castration-resistant prostate cancer.Enrichment of putative prostate cancer stem cells after androgen deprivation: upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines.A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease.3,3'-Diindolylmethane and genistein decrease the adverse effects of estrogen in LNCaP and PC-3 prostate cancer cells.Immunization against luteinizing hormone-releasing hormone fusion proteins does not decrease prostate cancer in the transgenic adenocarcinoma mouse prostate model.Androgen receptor gene mutation, rearrangement, polymorphism.Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide.Isolation and characterization of androgen receptor mutant, AR(M749L), with hypersensitivity to 17-beta estradiol treatment.Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer.Androgen receptor mutations are associated with Gleason score in localized prostate cancer.Androgen receptor mutations in high-grade prostate cancer before hormonal therapy.Prevention of Prostate Tumor Development by Stimulation of Antitumor Immunity Using a Standardized Herbal Extract (Deep Immune®) in TRAMP Mice.
P2860
Q24291571-86682279-5D1C-4044-8513-3297F3918EB9Q26858922-46556176-B201-4AC9-B417-7C075ADFA398Q27001047-55B0B4CF-CB17-4D34-8B1C-821EDBA2891BQ28258333-DAEA8832-6199-4303-8865-2CC95D103FA8Q28512229-744828B9-7F43-4546-B5BC-8B51ECCA768CQ33607836-B20027B7-0F35-4E58-A071-49432D0B9F15Q33732154-77C1A64B-98D8-4FCA-810D-BB464E7EA74EQ33940867-68F8ACB5-B30D-4EC0-B66A-FEDEFD6B9DD2Q34022799-BC9117B5-10CF-4319-B2E1-F57D922F6A81Q34133697-4B4D030D-F81E-44FF-80F7-6D8C83B9305BQ34425907-58BB8840-FA20-4C6C-A76D-182791F6E2FEQ34837015-7B9C2048-A20F-4230-9E0F-28FD22F24AB8Q35107605-62188BB6-4376-4083-AE71-39252FD93D9EQ35281575-CBA39F88-FCF8-473A-8DD5-B0F6EB177AF7Q36382025-84F39F9A-323E-444F-91D3-4E43CE18DFB1Q36503027-5AE8E64A-5D6A-4B64-AB9B-4B154C6F45F3Q37074958-CAF18D76-0718-4477-8822-D113C9983302Q37124560-970F253C-0838-45D1-890D-B075CFF144E4Q37147772-EB1B9886-EA39-42BC-AB07-209105FD5FC2Q37210875-65503A37-F35A-4DE1-B9F9-89ED3E21835BQ37357108-F0E4BDB3-DB53-4C4D-826E-5D120714092FQ37396357-4CF9A130-B91B-475E-B34E-9221197245D8Q37590123-E6F8BE08-E64E-4170-A69D-88423E7028B8Q37983730-9B21F9A1-9A8B-41C2-A3CC-112E096D1186Q38826609-5CD3C70E-0448-40F0-A1B1-98E58F85A21AQ39144729-785CC20C-B5F2-48F4-BBB1-645EA5AB737CQ39406777-0A4125C0-AD0F-44DA-8138-7B8E107A54F3Q39913846-9C3996F9-AD19-4A88-AD46-31D741D29577Q40573231-D1167C8F-6B9D-450F-9D09-8D51E5128E44Q42738421-50F48ADA-2D85-48B1-80D7-194F8CFCE788Q43821771-3F5D8746-ACA2-4A00-9E49-9D1E15997A1FQ44260466-AFC2B6D6-BF7F-4E1A-BF19-7F60AD353BA6Q44912912-DBE226BA-E4B6-40FC-AB2A-95E834F1764EQ54576747-86366565-1B9A-4245-A3CB-B4CC608EA0E7Q54736431-F22C8954-CB33-4930-98B4-584449FA9C57Q55401425-012F40FD-E950-4DBD-90A3-9E5620147148
P2860
Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer.
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Hormone status selects for spo ...... autochthonous prostate cancer.
@ast
Hormone status selects for spo ...... autochthonous prostate cancer.
@en
type
label
Hormone status selects for spo ...... autochthonous prostate cancer.
@ast
Hormone status selects for spo ...... autochthonous prostate cancer.
@en
prefLabel
Hormone status selects for spo ...... autochthonous prostate cancer.
@ast
Hormone status selects for spo ...... autochthonous prostate cancer.
@en
P2093
P2860
P4510
P356
P1476
Hormone status selects for spo ...... autochthonous prostate cancer
@en
P2093
P2860
P304
11204-11213
P356
10.1074/JBC.M008207200
P407
P577
2000-11-03T00:00:00Z